/
Ophthalmology
Macular Edema
37
Pipeline Programs↗
56
Active Trials↗
42
Companies Involved↗
Macular Edema is a moderately active landscape with 37 programs across 42 companies. The most active players are Kiora Pharmaceuticals, Inc.. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 19
Phase 29
Phase 35
Approved
No programs
Analysis
Modality Breakdown
81%
Small molecule
26 of 32 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 95% of 37 pipeline programs.
Analysis
Trial Status
410
clinical trials
Completed241 · 59%
Unknown status57 · 14%
Terminated29 · 7%
Withdrawn27 · 7%
Active, not recruiting22 · 5%
Recruiting22 · 5%
Other12 · 3%
Clinical Trials
Trial Activity
410 trials
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
Recruiting·—·Phase 1·NCT06781255·5 enrolled
Page 1 of 28
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)